Canature Health Technology Co., Ltd. (SHE:300272)
China · Delayed Price · Currency is CNY 5.12
-0.20 (-3.76%)
Jul 24, 2026, 3:04 PM CST
SHE:300272 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 1,800 | 1,796 | 1,679 | 1,659 | 1,645 | 1,489 |
Other Revenue | 45.41 | 45.41 | 44.96 | 12.51 | 15.67 | 22.71 |
| 1,846 | 1,841 | 1,724 | 1,672 | 1,661 | 1,511 | |
Revenue Growth (YoY) | 5.14% | 6.77% | 3.14% | 0.67% | 9.87% | 27.97% |
Cost of Revenue | 1,142 | 1,129 | 1,064 | 1,056 | 1,112 | 1,010 |
Gross Profit | 704.01 | 711.46 | 660.01 | 615.87 | 548.75 | 501.96 |
Selling, General & Admin | 420.23 | 423.91 | 425.75 | 384.05 | 346.17 | 304.05 |
Research & Development | 82.62 | 81.55 | 81.97 | 65 | 63.94 | 51.49 |
Other Operating Expenses | 4.92 | 5.25 | 5.61 | 5.83 | 9.04 | 3.26 |
Operating Expenses | 507.09 | 511.29 | 513.24 | 457.05 | 419.71 | 361.57 |
Operating Income | 196.92 | 200.17 | 146.77 | 158.82 | 129.04 | 140.39 |
Interest Expense | -46.16 | -44.87 | -41.84 | -28.44 | -16.85 | -16.28 |
Interest & Investment Income | 25.5 | 24.21 | 22.56 | 14.87 | 5.54 | 32.26 |
Currency Exchange Gain (Loss) | -12.98 | -12.98 | 19.75 | 9.58 | 10.12 | 0.84 |
Other Non Operating Income (Expenses) | -19.23 | -6.62 | -5.21 | -4.41 | -9.23 | -5.48 |
EBT Excluding Unusual Items | 144.05 | 159.91 | 142.03 | 150.41 | 118.63 | 151.72 |
Impairment of Goodwill | - | - | - | - | -15.32 | -5.82 |
Gain (Loss) on Sale of Investments | -59.67 | -55.88 | -25.49 | 4.66 | 2.6 | -2.43 |
Gain (Loss) on Sale of Assets | 0.32 | -0.24 | -0.74 | 2.33 | 1.4 | -0.7 |
Asset Writedown | -0.3 | - | - | - | - | -0.19 |
Legal Settlements | - | - | -3.73 | -0.24 | - | -3.71 |
Other Unusual Items | 5.91 | 6.4 | 9.68 | 1.64 | 6.96 | 6.61 |
Pretax Income | 90.3 | 110.19 | 121.75 | 158.81 | 114.27 | 145.49 |
Income Tax Expense | 27.37 | 30.12 | 21.49 | 5.33 | 15.24 | 28.39 |
Earnings From Continuing Operations | 62.93 | 80.07 | 100.26 | 153.48 | 99.03 | 117.1 |
Minority Interest in Earnings | -22.41 | -24.06 | -29.87 | -21.03 | -6.47 | -12.24 |
Net Income | 40.52 | 56.01 | 70.39 | 132.45 | 92.56 | 104.86 |
Net Income to Common | 40.52 | 56.01 | 70.39 | 132.45 | 92.56 | 104.86 |
Net Income Growth | -41.21% | -20.43% | -46.86% | 43.09% | -11.73% | 296.93% |
Shares Outstanding (Basic) | 593 | 580 | 566 | 562 | 566 | 583 |
Shares Outstanding (Diluted) | 593 | 580 | 573 | 573 | 566 | 583 |
Shares Change (YoY) | 4.45% | 1.34% | -0.03% | 1.19% | -2.82% | 10.26% |
EPS (Basic) | 0.07 | 0.10 | 0.12 | 0.24 | 0.16 | 0.18 |
EPS (Diluted) | 0.07 | 0.10 | 0.12 | 0.23 | 0.16 | 0.18 |
EPS Growth | -43.71% | -21.48% | -46.84% | 41.41% | -9.17% | 260.00% |
Free Cash Flow | 107.5 | 154.89 | 161.19 | 294.59 | 60.85 | 115.48 |
Free Cash Flow Per Share | 0.18 | 0.27 | 0.28 | 0.51 | 0.11 | 0.20 |
Dividend Per Share | 0.180 | 0.180 | 0.160 | 0.100 | 0.100 | 0.100 |
Dividend Growth | 12.50% | 12.50% | 60.00% | 0% | 0% | 100.00% |
Gross Margin | 38.14% | 38.65% | 38.28% | 36.84% | 33.04% | 33.21% |
Operating Margin | 10.67% | 10.87% | 8.51% | 9.50% | 7.77% | 9.29% |
Profit Margin | 2.20% | 3.04% | 4.08% | 7.92% | 5.57% | 6.94% |
Free Cash Flow Margin | 5.82% | 8.41% | 9.35% | 17.62% | 3.66% | 7.64% |
EBITDA | 259.08 | 260.92 | 201.89 | 208.85 | 181.79 | 183.42 |
EBITDA Margin | 14.04% | 14.17% | 11.71% | 12.49% | 10.95% | 12.13% |
D&A For EBITDA | 62.15 | 60.75 | 55.13 | 50.03 | 52.76 | 43.02 |
EBIT | 196.92 | 200.17 | 146.77 | 158.82 | 129.04 | 140.39 |
EBIT Margin | 10.67% | 10.87% | 8.51% | 9.50% | 7.77% | 9.29% |
Effective Tax Rate | 30.31% | 27.33% | 17.65% | 3.36% | 13.34% | 19.51% |
Revenue as Reported | 1,846 | 1,841 | 1,724 | 1,672 | 1,661 | 1,511 |
Advertising Expenses | - | 8.82 | 13.96 | 10.59 | 0.13 | 1.4 |